Divisions of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Divisions of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Trends Mol Med. 2017 Oct;23(10):945-961. doi: 10.1016/j.molmed.2017.08.006. Epub 2017 Sep 7.
Combination antiretroviral therapy (cART) induces durable suppression of virus replication but is unable to eradicate HIV. Invariably, virus rebound follows treatment interruption and life-long cART is thus required. Advances have been made in our understanding of HIV latency, identification of HIV cell reservoirs, regulation of HIV-specific immune responses, as well as in the development of broad neutralizing antibodies and putative therapeutic vaccines. These have provided a scientific basis to explore alternative strategies that achieve durable suppression of viremia in the absence of cART, the so-called functional cure. Single intervention strategies have shown promise, albeit with limited efficacy. Consequently, a combination of interventions aiming to stimulate the immune response and prevent new rounds of viral infection and spreading may render the HIV functional cure a feasible goal.
联合抗逆转录病毒疗法(cART)可诱导病毒复制的持久抑制,但无法根除 HIV。不可避免的是,治疗中断后病毒会反弹,因此需要终身接受 cART。我们在 HIV 潜伏期、HIV 细胞储库的鉴定、HIV 特异性免疫反应的调节以及广谱中和抗体和潜在治疗性疫苗的开发方面都取得了进展。这些为探索在没有 cART 的情况下实现病毒血症持久抑制的替代策略提供了科学依据,即所谓的功能性治愈。单一干预策略显示出了希望,但疗效有限。因此,旨在刺激免疫反应并防止新的病毒感染和传播的联合干预措施可能使 HIV 功能性治愈成为一个可行的目标。